November 17, 2016 - By Nellie Frank · 0 Comments
Nov 17 is a positive day so far for iShares Nasdaq Biotechnology (NASDAQ:IBB) as the ETF is active during the day after gaining 0.63% to hit $288.32 per share. The exchange traded fund has 8.44 billion net assets and 2.24% volatility this month.
Over the course of the day 1.02M shares traded hands, as compared to an average volume of 1.71 million over the last 30 days for iShares Nasdaq Biotechnology (NASDAQ:IBB).
The ETF is -16.12% of its 52-Week High and 20.16% of its low, and is currently having ATR of 7.89. This year’s performance is -14.75% while this quarter’s performance is -2.41%.
The ETF’s YTD performance is -24.02%, the 1 year is -21.01% and the 3 year is 7.85%.
The ETF’s average P/E ratio is 18.14, the price to book is 3.26, the price to sales is 4.65 and the price to cashflow is 9.14. It was started on 02/12/2001. The fund’s top holdings are: Celgene Corporation for 8.58% of assets, Gilead Sciences Inc. for 8.42%, Biogen Inc. for 8.22%, Amgen Inc. for 7.44%, Regeneron Pharmaceuticals Inc. for 6.90%, Alexion Pharmaceuticals Inc. for 4.65%, Mylan N.V. for 3.86%, Illumina Inc. for 3.62%, Vertex Pharmaceuticals Incorpor for 3.60%, Incyte Corporation for 3.24%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0.17% yield.
More notable recent iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) news were published by: Fool.com which released: “2 Reasons Why the iShares NASDAQ Biotechnology Index (ETF) Tumbled 11% in October” on November 07, 2016, also Investorplace.com with their article: “3 Big Stock Charts: iShares NASDAQ Biotechnology Index (ETF) (IBB …” published on November 09, 2016, Etfdailynews.com published: “These ETFs Are The Best And Worst Performers Since Trump’s Victory” on November 10, 2016. More interesting news about iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) were released by: Etfdailynews.com and their article: “BlackRock: Health Care Sector Sell-Off Overdone” published on October 20, 2016 as well as Etfdailynews.com‘s news article titled: “Biotech ETF Testing Critical Support Levels” with publication date: October 22, 2016.
iShares Nasdaq Biotechnology ETF , formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The ETF has a market cap of $8.44 billion. The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). It has a 3.17 P/E ratio. The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank